XERS
$11.13+1.64%
Xeris Biopharma Holdings Inc.Stock · HealthcareRussell 2000 · 0.04% of IWMRussell 3000 · 0.002% of IWVUS Stock Market · 0.002% of VTI
Xeris Biopharma Holdings Inc. total returns by year (including dividends)
As of market close, Oct 20, 2026
Xeris Biopharma Holdings Inc. total returns by year (2019–2026)#
Calendar-year returns with each year's path and its dividend contribution (dividend return = total minus price return). Every year has a direct link you can bookmark or share.
| Year | Start price | End price | Path | Dividend | Total return |
|---|---|---|---|---|---|
| 2026YTD | $7.85 | $11.13 | 0.0% | +41.8% | |
| 2025 | $3.39 | $7.85 | 0.0% | +131.6% | |
| 2024 | $2.35 | $3.39 | 0.0% | +44.3% | |
| 2023 | $1.33 | $2.35 | 0.0% | +76.7% | |
| 2022 | $2.93 | $1.33 | 0.0% | -54.6% | |
| 2021 | $4.92 | $2.93 | 0.0% | -40.4% | |
| 2020 | $7.05 | $4.92 | 0.0% | -30.2% | |
| 2019 | $17.00 | $7.05 | 0.0% | -58.5% |
- Annualized
- -6.2%
- 2019–2026
- Average year
- +9.8%
- 7 full years
- Best year
- +131.6%
- 2025
- Worst year
- -58.5%
- 2019
- Positive years
- 3/7
- 43% up
Annualized (CAGR)
-6.2%
2019–2026
Average year
+9.8%
7 full years
Best year
+131.6%
2025
Worst year
-58.5%
2019
Positive years
3/7
43% up
Total return by period#
Annual
-100%-50%0%50%100%
2019-59%'19
2020-30%'20
2021-40%'21
2022-55%'22
2023+77%'23
2024+44%'24
2025+132%'25
2026+42%'26
Methodology#
Total returns, dividends reinvested, measured on XERS. Annualized return is the compound annual growth rate; the current year is year-to-date. Past performance does not predict future returns.
FAQ#
- What is Xeris Biopharma Holdings Inc.'s average annual return?
- Since 2019, Xeris Biopharma Holdings Inc. (XERS) has returned about -6.2% a year (the compound annual growth rate) and an average calendar-year return of 9.8%.
- What were Xeris Biopharma Holdings Inc.'s best and worst years?
- Over 2019–2026, the best year was 2025 (+131.6%) and the worst was 2019 (-58.5%).
- How often is Xeris Biopharma Holdings Inc. up in a year?
- 3 of the 7 full years since 2019 were positive — about 43% of the time.
More on Xeris Biopharma Holdings Inc.
Annual returns for: S&P 500 · S&P 500 Equal Weight · US Stock Market · Nasdaq-100